The estimated Net Worth of Sean A. Mc Carthy is at least $5.47 Million dollars as of 20 August 2024. Sean Carthy owns over 37,500 units of CytomX Therapeutics Inc stock worth over $879,991 and over the last 9 years he sold CTMX stock worth over $818,509. In addition, he makes $3,769,930 as Chairman of the Board, President und Chief Executive Officer at CytomX Therapeutics Inc.
Sean has made over 40 trades of the CytomX Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 37,500 units of CTMX stock worth $49,125 on 20 August 2024.
The largest trade he's ever made was exercising 109,768 units of CytomX Therapeutics Inc stock on 26 March 2024 worth over $172,336. On average, Sean trades about 16,708 units every 43 days since 2016. As of 20 August 2024 he still owns at least 671,749 units of CytomX Therapeutics Inc stock.
You can see the complete history of Sean Carthy stock trades at the bottom of the page.
Dr. Sean A. McCarthy Ph.D. serves as Chairman of the Board, President, Chief Executive Officer of the Company. Dr. McCarthy has more than twenty years of experience in the biotechnology industry encompassing roles in R&D, business development, financing and general management. Following completion of his post-doctoral training at the DNAX Research Institute (now Merck Palo Alto), Dr. McCarthy held research leadership and program management roles at Millennium Pharmaceuticals where he managed biologics discovery programs. From Millennium, Dr. McCarthy joined SGX Pharmaceuticals, where he spearheaded a wide range of large pharma partnerships as vice president business development and helped drive a strategic reorientation of the company from a platform business model to product-focused oncology company, leading to a successful initial public offering in 2006. Immediately prior to joining CytomX, Dr. McCarthy was a transactional partner at Pappas Ventures from April 2006 to December 2010, where he was responsible for investments in therapeutic, medical device and molecular diagnostic companies. Dr. McCarthy is an author on multiple peer reviewed scientific publications, issued patents and filed patent applications. He received a B.Sc. in biochemistry and pharmacology at King’s College, University of London; an MBA from the Rady School of Management at the University of California San Diego; and a D.Phil. in cancer biology from St. John’s College, University of Oxford. Dr. McCarthy currently serves as a member of the Board of Directors of the California Life Sciences Association. McCarthy is qualified to serve on our Board based on his management experience in the life sciences sector, including at CytomX, his deep knowledge of the industry, and his strategic and business development expertise.
As the Chairman of the Board, President und Chief Executive Officer of CytomX Therapeutics Inc, the total compensation of Sean McCarthy at CytomX Therapeutics Inc is $3,769,930. There are no executives at CytomX Therapeutics Inc getting paid more.
Sean McCarthy is 53, he's been the Chairman of the Board, President und Chief Executive Officer of CytomX Therapeutics Inc since 2019. There are 14 older and 3 younger executives at CytomX Therapeutics Inc. The oldest executive at CytomX Therapeutics Inc is Frederick W. Gluck, 86, who is the Co-Founder & Independent Director.
Sean's mailing address filed with the SEC is C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., STE. 400, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 10 years, insiders at CytomX Therapeutics Inc have traded over $57,157,858 worth of CytomX Therapeutics Inc stock and bought 662,000 units worth $7,876,720 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Harbor Master Investors (Ca... und James E Deerfield Mgmt L.P..... On average, CytomX Therapeutics Inc executives and independent directors trade stock every 20 days with the average trade being worth of $48,707. The most recent stock trade was executed by Jeffrey B Landau on 20 August 2024, trading 11,250 units of CTMX stock currently worth $14,738.
cytomx is an oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its probody technology platform. the company uses the platform to create development-stage proprietary cancer immunotherapies against clinically-validated targets, as well as to develop first-in-class investigational cancer therapeutics against novel targets. cytomx believes that its probody platform has the potential to improve the combined efficacy and safety profile of monoclonal antibody modalities, including cancer immunotherapies, antibody drug conjugates and t-cell-recruiting bispecific antibodies. probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. investigational probody therapeutics are being developed that address clinically-validated cancer targets in immuno-oncology, such as pd-l1 against which o
CytomX Therapeutics Inc executives and other stock owners filed with the SEC include: